Dicot Pharma (DICOT) Q3 2026 earnings summary

Executive summary

• LIB-01 Phase 2b preparations progressed; initiation before year-end remains the target, with cash on hand stated to fund the planned study.

• Q3 and 9M net sales were SEK 0.0m; losses reflect clinical development costs and preclinical work.

Financial highlights

• Q3 operating loss was SEK 26.0m vs SEK 16.6m; loss after financial items and net loss were SEK 25.2m vs SEK 16.1m.

• 9M operating loss was SEK 59.7m vs SEK 65.2m; net loss was SEK 58.4m vs SEK 63.4m.

• Net sales were SEK 0.0m in Q3 and 9M; other operating income was SEK 0.0m in Q3 and SEK 0.1m for 9M.

• Q3 costs rose to SEK 26.1m from SEK 16.6m, mainly due to Phase 2b start-up preparations; development and other costs were SEK 23.4m vs SEK 14.5m.

Outlook and guidance

• Phase 2b initiation before year-end remains the plan; FDA clearance covers the US study's first part, while EU authority decision was expected in Q4.

• SEK 225.5m cash and cash equivalents were described as sufficient to conduct the planned Phase 2b study.

• A parallel preclinical program is assessing LIB-01 in metabolic disease indications; research findings indicate potential beyond erectile dysfunction.